Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
Therapeutic Potential of Compounds with High Affinity to BAG2 in Inhibiting Keloid Disease.
Journal: Biologics : targets & therapy
Published: June 03, 2025
The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis.
Journal: The Lancet regional health. Europe
Published: May 30, 2025
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
Journal: Journal of neurology
Published: May 23, 2025
S1P receptor 1 antagonist ponesimod alleviates postherpetic neuralgia in rats by normalizing spinal TRPV1 expression and inhibiting MAPK-mediated glial activation.
Journal: Cytotechnology
Published: May 12, 2025
De-Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria.
Journal: European journal of neurology
Published: April 14, 2025
A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults.
Journal: Clinical and translational science
Published: April 14, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis.
Journal: Neurology and therapy
Published: February 12, 2025
Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data.
Journal: Pharmacological reports : PR
Published: January 09, 2025
Activation of S1PR1 by Ponesimod for Multiple Sclerosis Therapy: Uncovering MAPK and PI3K Pathway Mechanisms and Repurposing Potential.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: December 26, 2024
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Journal: Multiple sclerosis and related disorders
Published: November 28, 2024
Last Updated: 10/31/2025